A Phase I first-in-human study in healthy volunteers with intravenously administered OMN6, a novel antimicrobial peptide targeting Acinetobacter baumannii
QPS worked closely with Omnix Medical Ltd. to present the results of a Phase I first-in-human study in healthy volunteers with intravenously administered OMN6.